MLYS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
60.1M
-75.6%
246.0M
+442.7%
45.3M
+18.4%
38.3M
-6.9%
41.1M
R&D
22.7M
-89.8%
221.4M
+808.6%
24.4M
-0.2%
24.4M
-22.4%
31.4M
SG&A
37.4M
+51.7%
24.7M
+17.6%
21.0M
+51.1%
13.9M
+43.4%
9.7M
Operating Income
-60087000
+75.6%
-246040000
-442.7%
-45340000
-18.4%
-38280000
+6.9%
-41131000
EBITDA
-60081000
+75.6%
-246035000
-442.7%
-45334000
-18.5%
-38267000
+6.9%
-41116000
Net Income
-57328000
+76.2%
-241071000
-512.8%
-39339000
-22.0%
-32234000
+12.7%
-36932000
EPS (Basic)
$-0.64
+77.5%
$-2.85
-506.4%
$-0.47
-17.5%
$-0.40
+23.1%
$-0.52
EPS (Diluted)
$-0.64
+77.5%
$-2.85
-506.4%
$-0.47
-17.5%
$-0.40
+23.1%
$-0.52
Shares (Diluted)
89.0M
+5.0%
84.7M
+2.3%
82.8M
+1.7%
81.4M
+15.3%
70.6M
Mineralys Therapeutics (MLYS) — Financials